Loading...
Loading...
MIRA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 2,081.6K |
| Gross Profit | -2,081.6K |
| Operating Expense | 2,081.6K |
| Operating I/L | -2,081.6K |
| Other Income/Expense | 37.8K |
| Interest Income | 37.8K |
| Pretax | -2,043.9K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -2,043.9K |
MIRA Pharmaceuticals, Inc. is a clinical development stage biopharmaceutical company specializing in the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog, MIRA1a, for the treatment of anxiety and cognitive decline in early-stage dementia patients. The company's focus is on developing synthetic cannabinoid analogs to target cannabinoid type 1 and type 2 receptors for the treatment of anxiety and chronic pain in adult patients.
